Definitive Contract 75N93023C00047
Award Date
9/30/23
Potential Completion Date
9/29/28
Potential Value
$7.9M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
University Of Montana
Ultimate Awardee
Not listed
NAICS Category
541512 - Computer Systems Design Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Missoula, MT 59812, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
24
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This is a $10,172,188 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the University of Montana for a Vaccine Adjuvant Discovery Program. The contract involves research to identify and characterize novel, effective, and safe vaccine adjuvants, including high-throughput screening, mechanism of action studies, lead compound optimization, and in vivo efficacy testing. The...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...
This is a non-severable definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to the University of Montana for a base period of three years from September 30, 2018, to September 29, 2021, with a total potential value of $18,280,011.02 and an ultimate completion date of July 14, 2025. The contract is a cost-no-fee arrangement and does not have a set-aside designation. The...
This is a $9,983,467.70 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract has a period of performance through April 30, 2026 and was originally solicited through a Broad Agency Announcement issued by NIAID in 2018. The University of Chicago is collaborating with the IIT Research Institute and the University of...
This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...
This federal contract award, valued at $8,762,844.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (DHHS). The contract was awarded to the University of California, Irvine (UC Irvine) to conduct a research program comparing multiple vaccine adjuvants across various platforms. The goal is to establish immunological profiles of the adjuvants' strength,...
This is a $9,807,060 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Chicago. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which aims to evaluate and develop animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. This contract is not set-aside and is a cost-type...
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), a civilian agency. The contract was awarded to the University of Maryland, Baltimore (UMB) on April 10, 2015 and has a ceiling value of $882,112.66. It is a task order under the Vaccine and Treatment Evaluation Units (VTEU) Indefinite Delivery Vehicle (IDV), which allows NIAID to place orders for medical research and services...